John Cush
Rheumatology · Dallas, TXNPI 1265492680
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,477,368 of the $3,696,836 with a category attached, or 67.0%. AbbVie accounts for 63.6% of it on its own, with 18 other manufacturers making up the rest. Among rheumatology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 632 payments — averaging $5849.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2.4M
- Novartis$789K
- E.r. Squibb & Sons, L.L.C.$398K
- UCB, Inc.$48K
- Pfizer$34K
- Genentech USA, Inc.$29K
- plus $49K from 13 others
Across 31 payments — averaging $8000.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$164K
- AbbVie$49K
- Swedish Orphan Biovitrum AB$35K
What the payments were for
- Consulting fees$263,6557%
- Speaking & faculty fees$2,477,36867%
- Grants$909,50025%
- Travel & lodging$39,8681%
- Food & beverage$6,3780%
- Education$660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 129 | $2,350,050 |
| Novartis | 136 | $788,541 |
| E.r. Squibb & Sons, L.L.C. | 61 | $397,601 |
| UCB, Inc. | 42 | $48,445 |
| Pfizer | 61 | $34,170 |
| Genentech USA, Inc. | 11 | $29,154 |
| Janssen Scientific Affairs, LLC | 117 | $16,016 |
| Amgen | 6 | $7,120 |
| Gilead | 7 | $6,636 |
| Eli Lilly | 1 | $5,600 |
| Lilly USA, LLC | 10 | $5,360 |
| UCB SA | 1 | $3,750 |
| Sanofi | 17 | $2,842 |
| Genentech, Inc. | 19 | $813 |
| Assertio Therapeutics, Inc. | 2 | $355 |
| Aurinia Pharma U.S., Inc. | 9 | $250 |
| AstraZeneca | 1 | $53 |
| Medline Industries LP | 1 | $47 |
| Boehringer Ingelheim | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,696,836 in reported general payments places this provider in the 95th percentile of 512 rheumatology providers in Texas.
Other rheumatology in Dallas
- Zoran KurepaDallas$483K
- Giovanni GeslaniDallas$415K
- Dianne PetroneDallas$401K
- Stanley CohenDallas$318K
- Joanna GeslaniDallas$242K
- Sharad LakhanpalDallas$229K
- Iftikhar ChowdhryDallas$226K
- Srilatha KothandaramanDallas$140K
- Leyka BarbosaDallas$108K
- Robert JenkinsDallas$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.